The New York Times (7/25, Belluck) reports, “The long-elusive quest for a medication that works to treat Alzheimer’s reached a potentially promising milestone” yesterday. According to the Times, “for the first time in a large clinical trial, a drug was able to both reduce the plaques in the brains of patients and slow the progression of dementia.” The Wall Street Journal (7/25, Loftus, Subscription Publication) reports that the findings on the drug, known as BAN2401, were presented at the Alzheimer’s Association International Conference. Reuters (7/25, Steenhuysen) reports that the drug’s developers, “Biogen Inc. and partner Eisai Co. Ltd., said patients with early-stage Alzheimer’s disease treated with their experimental drug…experienced 30 percent less cognitive decline than those who got a placebo.” Meanwhile, “the second-highest dose of the drug also showed some benefit, but did not meet statistical significance, according to” the data. Reuters adds, “BAN2401 demonstrated a dose-dependent reduction in amyloid plaques that was statistically significant at all doses tested, researchers said.” (SOURCE: APA Headlines)
- ) strategy and implementation of activities aimed at increased supports for caregivers of persons with mental illness, in addition to the continued work of the Coalition and sustaining the collaboration between aging and behavioral health providers at the local level.
- Studies Support Effectiveness Of Ketamine, Esketamine For Difficult-To-Treat Depression, MDD With Suicidal Ideation, Expert Says
- In Small Study, Investigational Nondopamine Antipsychotic Show Signals It May Improve Psychosis Symptoms In Patients With Parkinson’s Disease
- Benzoate Treatment Appears To Improve Cognitive Function Among Women With Later-Stage Dementia In Small Study
- More Than One In Ten Patients Who Receive An ICD May Also Develop Anxiety Or Depression, Research Suggests